✦ LIBER ✦

A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer

✍ Scribed by Natsuko T. Okita, Taito Esaki, Eishi Baba, Daisuke Sakai, Shinya Tokunaga, Hiroya Takiuchi, Nobuyuki Mizunuma, Kengo Nagashima, Ken Kato

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Axitinib and/or bevacizumab with modifie

✍ Infante, Jeffrey R.; Reid, Tony R.; Cohn, Allen L.; Edenfield, William J.; Cesco 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

A Phase II Trial of FOLFOX6 and Cetuxima

✍ Ralph V. Boccia; Thomas M. Cosgriff; David L. Headley; Suprith Badarinath; Shake 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 410 KB

Phase II study of FOLFOX, bevacizumab an

✍ Meyerhardt, J.; Stuart, K.; Fuchs, C.; Zhu, A.; Earle, C.; Bhargava, P.; Blaszko 📂 Article 📅 2007 🏛 Oxford University Press 🌐 English ⚖ 84 KB

Front-line Bevacizumab in combination wi

✍ Christos Emmanouilides; Georgia Sfakiotaki; Nikolaos Androulakis; Kostas Kalbaki 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 263 KB

FOLFIRI plus bevacizumab as a first-line

✍ Kochi, Mitsugu; Akiyama, Yuji; Aoki, Tatsuya; Hagiwara, Ken; Takahashi, Takao; H 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 453 KB

Axitinib or Bevacizumab Plus FOLFIRI or

✍ Bendell, Johanna C.; Tournigand, Christophe; Swieboda-Sadlej, Anna; Barone, Carl 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 292 KB